Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Natl. Right to Life Committee

Executive Summary

Has proposed guidelines for amending FDA regulations for testing of contraceptives. Group is recommending that no FDA funds be used "to perform any function with respect to" the IND in effect for Hoechst's mifepristone (RU-486), which is being studied as a contraceptive and abortant. Group also supports requirement that all oral contraceptives and devices have "mandatory 7 and 10 year dog and monkey trials" prior to initiating clinicals. The recommendations were resented to FDA at a June 12 meeting as proposed revisions to the guidelines for testing oral contraceptives.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012209

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel